| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 278 | 2024 | 5595 | 14.610 |
Why?
|
| Skin Neoplasms | 203 | 2024 | 4883 | 11.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 75 | 2023 | 1451 | 6.370 |
Why?
|
| Lymph Node Excision | 50 | 2023 | 2056 | 2.690 |
Why?
|
| Neoplasm Staging | 106 | 2024 | 13998 | 2.600 |
Why?
|
| Lymphatic Metastasis | 81 | 2022 | 4956 | 2.450 |
Why?
|
| Lymph Nodes | 44 | 2023 | 3070 | 1.910 |
Why?
|
| Sentinel Lymph Node | 6 | 2021 | 229 | 1.690 |
Why?
|
| Humans | 309 | 2024 | 270465 | 1.090 |
Why?
|
| Prognosis | 79 | 2024 | 22477 | 1.010 |
Why?
|
| Medical Oncology | 7 | 2023 | 1463 | 0.970 |
Why?
|
| Practice Guidelines as Topic | 14 | 2021 | 2395 | 0.930 |
Why?
|
| Proto-Oncogene Proteins B-raf | 16 | 2022 | 1327 | 0.920 |
Why?
|
| Lymphangiogenesis | 3 | 2012 | 44 | 0.850 |
Why?
|
| Mitotic Index | 6 | 2023 | 162 | 0.820 |
Why?
|
| Melanoma, Experimental | 6 | 2021 | 382 | 0.730 |
Why?
|
| Sunbathing | 2 | 2016 | 10 | 0.690 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2023 | 10384 | 0.650 |
Why?
|
| Biomarkers, Tumor | 24 | 2021 | 10694 | 0.610 |
Why?
|
| United States | 34 | 2024 | 15855 | 0.600 |
Why?
|
| Sunburn | 3 | 2016 | 35 | 0.600 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 93 | 0.600 |
Why?
|
| Primary Prevention | 2 | 2018 | 234 | 0.590 |
Why?
|
| Neoplasms, Second Primary | 4 | 2023 | 1387 | 0.590 |
Why?
|
| Risk Assessment | 16 | 2020 | 6776 | 0.580 |
Why?
|
| Middle Aged | 129 | 2023 | 90080 | 0.580 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 356 | 0.570 |
Why?
|
| Male | 144 | 2024 | 128118 | 0.570 |
Why?
|
| Carcinoma, Merkel Cell | 5 | 2023 | 172 | 0.540 |
Why?
|
| Female | 145 | 2023 | 148658 | 0.520 |
Why?
|
| Interferon-alpha | 6 | 2016 | 959 | 0.520 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 7 | 2020 | 1017 | 0.520 |
Why?
|
| CTLA-4 Antigen | 8 | 2023 | 678 | 0.510 |
Why?
|
| Tanning | 1 | 2014 | 2 | 0.500 |
Why?
|
| Fellowships and Scholarships | 3 | 2019 | 410 | 0.490 |
Why?
|
| Adult | 100 | 2024 | 81750 | 0.490 |
Why?
|
| Sunscreening Agents | 2 | 2016 | 35 | 0.480 |
Why?
|
| Drug Labeling | 1 | 2014 | 29 | 0.480 |
Why?
|
| Ultraviolet Rays | 7 | 2023 | 585 | 0.470 |
Why?
|
| Aged | 93 | 2024 | 73153 | 0.470 |
Why?
|
| Databases, Factual | 14 | 2019 | 2234 | 0.460 |
Why?
|
| Surgical Oncology | 4 | 2020 | 211 | 0.460 |
Why?
|
| Lymphedema | 8 | 2017 | 239 | 0.460 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 5225 | 0.440 |
Why?
|
| Uveal Neoplasms | 3 | 2024 | 194 | 0.420 |
Why?
|
| Tumor Burden | 7 | 2019 | 2031 | 0.420 |
Why?
|
| Aged, 80 and over | 57 | 2023 | 30934 | 0.420 |
Why?
|
| Neoplasm Metastasis | 20 | 2020 | 5308 | 0.410 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2012 | 5 | 0.410 |
Why?
|
| Immunotherapy | 17 | 2023 | 3550 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 6 | 2023 | 4140 | 0.400 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2023 | 981 | 0.400 |
Why?
|
| Survival Analysis | 27 | 2022 | 9293 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 6 | 2022 | 2391 | 0.400 |
Why?
|
| Health Policy | 1 | 2014 | 282 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 4649 | 0.400 |
Why?
|
| Mutation | 23 | 2024 | 15904 | 0.400 |
Why?
|
| Societies, Medical | 5 | 2017 | 1320 | 0.390 |
Why?
|
| Endothelial Cells | 5 | 2015 | 1037 | 0.390 |
Why?
|
| Conjunctival Neoplasms | 3 | 2003 | 124 | 0.390 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2021 | 1094 | 0.390 |
Why?
|
| Lysophospholipids | 1 | 2012 | 148 | 0.380 |
Why?
|
| Interleukin-8 | 2 | 2012 | 531 | 0.370 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 627 | 0.370 |
Why?
|
| SEER Program | 5 | 2018 | 1049 | 0.360 |
Why?
|
| Disease-Free Survival | 28 | 2022 | 10261 | 0.360 |
Why?
|
| Neoplasms | 13 | 2023 | 15897 | 0.340 |
Why?
|
| Drug Eruptions | 1 | 2012 | 271 | 0.340 |
Why?
|
| Biopsy | 16 | 2019 | 3385 | 0.340 |
Why?
|
| Neovascularization, Pathologic | 6 | 2011 | 1585 | 0.330 |
Why?
|
| Adolescent | 43 | 2024 | 32701 | 0.330 |
Why?
|
| Risk Factors | 30 | 2023 | 17832 | 0.320 |
Why?
|
| Predictive Value of Tests | 16 | 2019 | 4942 | 0.320 |
Why?
|
| Radionuclide Imaging | 8 | 2011 | 656 | 0.320 |
Why?
|
| Positron-Emission Tomography | 6 | 2014 | 2196 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2020 | 5773 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 558 | 0.310 |
Why?
|
| Watchful Waiting | 3 | 2021 | 293 | 0.310 |
Why?
|
| Retrospective Studies | 46 | 2023 | 39761 | 0.310 |
Why?
|
| Nevus | 4 | 2021 | 116 | 0.310 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2024 | 199 | 0.310 |
Why?
|
| Multivariate Analysis | 18 | 2020 | 4323 | 0.300 |
Why?
|
| Survival Rate | 24 | 2022 | 12513 | 0.290 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 221 | 0.290 |
Why?
|
| Specialties, Surgical | 1 | 2009 | 134 | 0.290 |
Why?
|
| International Cooperation | 1 | 2008 | 325 | 0.280 |
Why?
|
| Immunohistochemistry | 12 | 2020 | 7647 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 9040 | 0.280 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 700 | 0.280 |
Why?
|
| Nomograms | 2 | 2020 | 313 | 0.280 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 5 | 2003 | 113 | 0.280 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 533 | 0.280 |
Why?
|
| Lymphatic System | 2 | 2006 | 55 | 0.270 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 229 | 0.270 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 42 | 0.270 |
Why?
|
| Lymphatic Vessels | 3 | 2015 | 138 | 0.270 |
Why?
|
| Proportional Hazards Models | 19 | 2024 | 5092 | 0.270 |
Why?
|
| Endothelium, Lymphatic | 2 | 2015 | 14 | 0.260 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 2355 | 0.260 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 5140 | 0.260 |
Why?
|
| Genome-Wide Association Study | 6 | 2020 | 2347 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 2570 | 0.250 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 66 | 0.250 |
Why?
|
| Case-Control Studies | 20 | 2023 | 6201 | 0.250 |
Why?
|
| Tomography, Emission-Computed | 1 | 2006 | 335 | 0.250 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 30 | 0.250 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2024 | 225 | 0.240 |
Why?
|
| Genes, ras | 3 | 2013 | 679 | 0.240 |
Why?
|
| Polymorphism, Genetic | 6 | 2008 | 1557 | 0.240 |
Why?
|
| Body Mass Index | 5 | 2023 | 2238 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2003 | 12 | 0.230 |
Why?
|
| Internship and Residency | 3 | 2020 | 1441 | 0.230 |
Why?
|
| Precision Medicine | 3 | 2017 | 1207 | 0.230 |
Why?
|
| Radiopharmaceuticals | 4 | 2006 | 1341 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 1265 | 0.220 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 15198 | 0.220 |
Why?
|
| Survivors | 3 | 2016 | 1022 | 0.220 |
Why?
|
| Evidence-Based Medicine | 5 | 2016 | 1037 | 0.220 |
Why?
|
| Dermatologic Surgical Procedures | 4 | 2019 | 108 | 0.220 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 1556 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 383 | 0.220 |
Why?
|
| Antineoplastic Agents | 14 | 2016 | 14622 | 0.210 |
Why?
|
| Child | 24 | 2022 | 30536 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 12 | 2018 | 4044 | 0.210 |
Why?
|
| Guideline Adherence | 3 | 2015 | 627 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2019 | 3993 | 0.210 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 414 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 624 | 0.210 |
Why?
|
| Skin Ulcer | 4 | 2013 | 73 | 0.210 |
Why?
|
| Biomedical Research | 5 | 2021 | 797 | 0.210 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2023 | 527 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 698 | 0.200 |
Why?
|
| Cohort Studies | 16 | 2021 | 9467 | 0.200 |
Why?
|
| Patient Selection | 4 | 2020 | 2030 | 0.200 |
Why?
|
| DNA-Binding Proteins | 8 | 2016 | 5001 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 2354 | 0.200 |
Why?
|
| Italy | 5 | 2023 | 186 | 0.200 |
Why?
|
| Fibrosarcoma | 1 | 2002 | 142 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 231 | 0.190 |
Why?
|
| Incidence | 9 | 2020 | 5814 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 102 | 0.190 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2012 | 51 | 0.190 |
Why?
|
| Australia | 5 | 2021 | 262 | 0.190 |
Why?
|
| Young Adult | 24 | 2020 | 22149 | 0.190 |
Why?
|
| Transcription Factor AP-2 | 4 | 2006 | 78 | 0.190 |
Why?
|
| Mice | 25 | 2022 | 35572 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 551 | 0.190 |
Why?
|
| Dermatology | 2 | 2019 | 72 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 129 | 0.190 |
Why?
|
| Disease Progression | 12 | 2023 | 6828 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 1336 | 0.190 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 1176 | 0.180 |
Why?
|
| Skin | 4 | 2018 | 1270 | 0.180 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 6182 | 0.180 |
Why?
|
| Genes, Dominant | 1 | 2001 | 356 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 1261 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 131 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 316 | 0.180 |
Why?
|
| Policy | 1 | 2020 | 53 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 157 | 0.170 |
Why?
|
| Ipilimumab | 3 | 2023 | 759 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 1308 | 0.170 |
Why?
|
| Frozen Sections | 2 | 2014 | 112 | 0.170 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 4956 | 0.170 |
Why?
|
| DNA Repair | 5 | 2013 | 1910 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 1013 | 0.170 |
Why?
|
| Internationality | 2 | 2011 | 206 | 0.170 |
Why?
|
| Health Promotion | 2 | 2021 | 510 | 0.170 |
Why?
|
| Treatment Outcome | 26 | 2023 | 33730 | 0.170 |
Why?
|
| Sunlight | 5 | 2018 | 80 | 0.170 |
Why?
|
| B7 Antigens | 1 | 2020 | 84 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 88 | 0.170 |
Why?
|
| Dermoscopy | 1 | 2019 | 15 | 0.170 |
Why?
|
| Interleukin-6 | 3 | 2021 | 1051 | 0.160 |
Why?
|
| Neck | 2 | 2020 | 394 | 0.160 |
Why?
|
| Models, Theoretical | 2 | 2018 | 806 | 0.160 |
Why?
|
| Mice, Nude | 11 | 2019 | 4329 | 0.160 |
Why?
|
| Lymphoscintigraphy | 1 | 1999 | 35 | 0.160 |
Why?
|
| Animals | 30 | 2022 | 61994 | 0.160 |
Why?
|
| Signal Transduction | 8 | 2018 | 12100 | 0.160 |
Why?
|
| Prospective Studies | 18 | 2023 | 13376 | 0.160 |
Why?
|
| Up-Regulation | 6 | 2020 | 2421 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 84 | 0.160 |
Why?
|
| Pathologists | 1 | 2019 | 97 | 0.160 |
Why?
|
| Smartphone | 1 | 2019 | 48 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2018 | 1185 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 240 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 295 | 0.160 |
Why?
|
| Cell Division | 1 | 2023 | 2661 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 130 | 0.160 |
Why?
|
| Rosaniline Dyes | 4 | 2004 | 109 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2019 | 119 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 384 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 315 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 530 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.150 |
Why?
|
| Lung Neoplasms | 6 | 2022 | 12020 | 0.150 |
Why?
|
| Neuregulin-1 | 1 | 2018 | 89 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 560 | 0.150 |
Why?
|
| Medical Records | 1 | 2019 | 445 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 290 | 0.150 |
Why?
|
| Radiation-Protective Agents | 1 | 2018 | 129 | 0.150 |
Why?
|
| Receptor, ErbB-3 | 1 | 2018 | 126 | 0.150 |
Why?
|
| Europe | 4 | 2024 | 656 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 7091 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 161 | 0.150 |
Why?
|
| Ulcer | 1 | 2018 | 79 | 0.150 |
Why?
|
| DNA Primers | 5 | 2013 | 1497 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 262 | 0.150 |
Why?
|
| Pathology | 1 | 2018 | 98 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 6256 | 0.150 |
Why?
|
| Lymphatic Irradiation | 3 | 2008 | 139 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 7 | 2022 | 4476 | 0.150 |
Why?
|
| Confidence Intervals | 6 | 2019 | 748 | 0.140 |
Why?
|
| Odds Ratio | 9 | 2019 | 2299 | 0.140 |
Why?
|
| Beauty Culture | 1 | 2016 | 4 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 16645 | 0.140 |
Why?
|
| Genome, Human | 3 | 2018 | 1884 | 0.140 |
Why?
|
| Mentoring | 1 | 2019 | 101 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 1998 | 249 | 0.140 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 3939 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 855 | 0.140 |
Why?
|
| Receptors, Calcitriol | 2 | 2008 | 140 | 0.140 |
Why?
|
| Clinical Trials as Topic | 7 | 2019 | 3847 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 191 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 619 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 310 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2018 | 1840 | 0.140 |
Why?
|
| DNA Methylation | 3 | 2022 | 2764 | 0.140 |
Why?
|
| Mitosis | 3 | 2013 | 680 | 0.130 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2016 | 41 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2023 | 2270 | 0.130 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2016 | 52 | 0.130 |
Why?
|
| Melanocytes | 3 | 2021 | 240 | 0.130 |
Why?
|
| American Cancer Society | 1 | 2016 | 35 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 402 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 139 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2015 | 483 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 318 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 663 | 0.130 |
Why?
|
| Mastectomy | 3 | 2015 | 1553 | 0.130 |
Why?
|
| Minors | 1 | 2015 | 8 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 486 | 0.130 |
Why?
|
| Inflammation | 2 | 2019 | 2510 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2015 | 18 | 0.130 |
Why?
|
| Texas | 9 | 2020 | 6434 | 0.130 |
Why?
|
| Cytokines | 3 | 2019 | 2822 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 764 | 0.120 |
Why?
|
| Pyridones | 1 | 2018 | 360 | 0.120 |
Why?
|
| Nuclear Proteins | 6 | 2014 | 3440 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 189 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 3654 | 0.120 |
Why?
|
| Mutagens | 1 | 2016 | 191 | 0.120 |
Why?
|
| Inosine | 1 | 2015 | 42 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 637 | 0.120 |
Why?
|
| Recombinant Proteins | 5 | 2016 | 3027 | 0.120 |
Why?
|
| Antibodies | 2 | 2015 | 808 | 0.120 |
Why?
|
| Cell Line, Tumor | 11 | 2021 | 14830 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 7785 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 3397 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 235 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 619 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2075 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 256 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 3607 | 0.120 |
Why?
|
| Combined Modality Therapy | 6 | 2023 | 9043 | 0.120 |
Why?
|
| Metalloproteins | 1 | 2014 | 25 | 0.120 |
Why?
|
| RNA Editing | 1 | 2015 | 97 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2019 | 975 | 0.120 |
Why?
|
| Heterografts | 1 | 2017 | 741 | 0.120 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 314 | 0.120 |
Why?
|
| Leptin | 1 | 2016 | 305 | 0.120 |
Why?
|
| Freezing | 1 | 2014 | 62 | 0.120 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 6683 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 5407 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 2197 | 0.110 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 100 | 0.110 |
Why?
|
| Integrin alpha4 | 2 | 2011 | 26 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 19 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 262 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2015 | 5438 | 0.110 |
Why?
|
| Time Factors | 8 | 2019 | 12996 | 0.110 |
Why?
|
| Ribosomal Proteins | 1 | 2014 | 134 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1424 | 0.110 |
Why?
|
| Thioredoxins | 1 | 2013 | 50 | 0.110 |
Why?
|
| Obesity | 4 | 2023 | 2907 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 687 | 0.110 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1095 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 324 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 286 | 0.110 |
Why?
|
| Algorithms | 4 | 2019 | 3919 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 703 | 0.110 |
Why?
|
| Genotype | 8 | 2020 | 4251 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 4830 | 0.110 |
Why?
|
| Logistic Models | 5 | 2019 | 3439 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 2641 | 0.110 |
Why?
|
| Interferons | 2 | 2007 | 299 | 0.110 |
Why?
|
| Adenosine | 1 | 2015 | 297 | 0.110 |
Why?
|
| Surgeons | 1 | 2019 | 487 | 0.100 |
Why?
|
| MicroRNAs | 3 | 2022 | 2889 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 2 | 2012 | 1135 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 138 | 0.100 |
Why?
|
| Age Factors | 7 | 2016 | 5467 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 1280 | 0.100 |
Why?
|
| Registries | 2 | 2017 | 2203 | 0.100 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1553 | 0.100 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2012 | 89 | 0.100 |
Why?
|
| Cell Movement | 3 | 2012 | 2472 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 553 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1058 | 0.100 |
Why?
|
| Base Sequence | 6 | 2015 | 5433 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 1017 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 809 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2016 | 262 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 342 | 0.100 |
Why?
|
| Chi-Square Distribution | 5 | 2012 | 1310 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 356 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1468 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 5758 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1402 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1655 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 5923 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2024 | 1901 | 0.100 |
Why?
|
| Mammaplasty | 1 | 1998 | 714 | 0.090 |
Why?
|
| Metalloproteases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Phosphotransferases | 1 | 2011 | 82 | 0.090 |
Why?
|
| Exons | 2 | 2011 | 1382 | 0.090 |
Why?
|
| Mutagenesis | 1 | 2012 | 519 | 0.090 |
Why?
|
| Population Surveillance | 2 | 2012 | 648 | 0.090 |
Why?
|
| Medicine | 1 | 2012 | 139 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 232 | 0.090 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2024 | 40 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 608 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 787 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2010 | 114 | 0.090 |
Why?
|
| Inguinal Canal | 1 | 2010 | 64 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 5073 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 559 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2012 | 5690 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 1990 | 187 | 0.080 |
Why?
|
| Genetic Variation | 3 | 2006 | 2165 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2013 | 552 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 125 | 0.080 |
Why?
|
| Caspase 10 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Biomarkers | 2 | 2021 | 5049 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2011 | 501 | 0.080 |
Why?
|
| Apoptosis | 4 | 2013 | 7753 | 0.080 |
Why?
|
| Quality of Life | 4 | 2015 | 4772 | 0.080 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 908 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2012 | 889 | 0.080 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2021 | 168 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 6 | 2006 | 2455 | 0.080 |
Why?
|
| Risk | 4 | 2016 | 1939 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2017 | 5675 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2008 | 51 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 3213 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 146 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 268 | 0.080 |
Why?
|
| Chemoprevention | 2 | 2018 | 251 | 0.080 |
Why?
|
| Seroma | 1 | 2008 | 78 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2020 | 757 | 0.080 |
Why?
|
| Data Collection | 1 | 2011 | 624 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2014 | 1140 | 0.080 |
Why?
|
| Pandemics | 3 | 2024 | 1596 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 537 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 485 | 0.080 |
Why?
|
| Consensus | 3 | 2020 | 1102 | 0.080 |
Why?
|
| Haplotypes | 4 | 2013 | 910 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 3 | 2015 | 338 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2011 | 766 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 1095 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 138 | 0.070 |
Why?
|
| Intraoperative Period | 3 | 2005 | 252 | 0.070 |
Why?
|
| Intraoperative Care | 2 | 2007 | 274 | 0.070 |
Why?
|
| Radiography | 3 | 2008 | 1989 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1016 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2388 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2007 | 56 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1340 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2015 | 668 | 0.070 |
Why?
|
| Mass Screening | 1 | 2015 | 1548 | 0.070 |
Why?
|
| Clone Cells | 2 | 2020 | 587 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 16184 | 0.070 |
Why?
|
| Neurofibromatoses | 1 | 2006 | 18 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 499 | 0.070 |
Why?
|
| False Negative Reactions | 3 | 2009 | 284 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 265 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1542 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 603 | 0.070 |
Why?
|
| Receptor, PAR-1 | 1 | 2006 | 32 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2006 | 258 | 0.070 |
Why?
|
| CpG Islands | 1 | 2009 | 671 | 0.070 |
Why?
|
| Back | 1 | 2006 | 49 | 0.070 |
Why?
|
| Patient Care Planning | 2 | 2006 | 303 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2012 | 1573 | 0.070 |
Why?
|
| Adrenalectomy | 2 | 2023 | 195 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| Models, Biological | 2 | 2012 | 3196 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 481 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2015 | 820 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2008 | 671 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 65 | 0.070 |
Why?
|
| Chromatids | 1 | 2005 | 84 | 0.060 |
Why?
|
| Cell Survival | 1 | 2012 | 3061 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2011 | 1471 | 0.060 |
Why?
|
| Lipoprotein Lipase | 1 | 1985 | 67 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2006 | 372 | 0.060 |
Why?
|
| Galectin 3 | 1 | 2006 | 131 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2013 | 7241 | 0.060 |
Why?
|
| Histones | 1 | 2013 | 1513 | 0.060 |
Why?
|
| Extremities | 2 | 2006 | 309 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 3148 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 513 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2012 | 1561 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1716 | 0.060 |
Why?
|
| Exome | 3 | 2016 | 1249 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2001 | 1580 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 1578 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 316 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 902 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2011 | 2439 | 0.060 |
Why?
|
| New York | 1 | 2023 | 102 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 257 | 0.050 |
Why?
|
| Sweden | 1 | 2003 | 86 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2007 | 1553 | 0.050 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 175 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 274 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 3356 | 0.050 |
Why?
|
| Transfection | 3 | 2008 | 3118 | 0.050 |
Why?
|
| Epidermis | 1 | 2003 | 196 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 260 | 0.050 |
Why?
|
| Axilla | 3 | 2015 | 933 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2002 | 29 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2023 | 131 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2011 | 1247 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 289 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 678 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 4568 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2017 | 1932 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 7924 | 0.050 |
Why?
|
| Transcriptome | 2 | 2022 | 1954 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 183 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2024 | 175 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4135 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2003 | 2364 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 51 | 0.050 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2003 | 182 | 0.050 |
Why?
|
| Decision Making | 3 | 2016 | 1251 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 1208 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2013 | 3592 | 0.050 |
Why?
|
| Diet | 2 | 2021 | 1481 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2001 | 84 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 7883 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2001 | 186 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2001 | 168 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 236 | 0.050 |
Why?
|
| Eyelid Neoplasms | 1 | 2003 | 193 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 210 | 0.050 |
Why?
|
| Lovastatin | 1 | 2001 | 56 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2010 | 1121 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2021 | 136 | 0.050 |
Why?
|
| Ligands | 2 | 2015 | 1016 | 0.050 |
Why?
|
| Recurrence | 2 | 2000 | 4877 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4960 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 76 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2024 | 504 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2001 | 726 | 0.040 |
Why?
|
| Culture Media | 1 | 2001 | 343 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2001 | 278 | 0.040 |
Why?
|
| Point Mutation | 3 | 2013 | 788 | 0.040 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 74 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 138 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 43 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 116 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1137 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 283 | 0.040 |
Why?
|
| Safety | 1 | 2001 | 464 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 295 | 0.040 |
Why?
|
| Arm | 2 | 2015 | 138 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 79 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2020 | 6394 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2145 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 236 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 35 | 0.040 |
Why?
|
| Cell Communication | 2 | 2015 | 513 | 0.040 |
Why?
|
| Membrane Proteins | 3 | 2015 | 2928 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2001 | 635 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Endonucleases | 2 | 2013 | 184 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2013 | 1462 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 318 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 106 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 443 | 0.040 |
Why?
|
| Thorax | 1 | 2000 | 232 | 0.040 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 1080 | 0.040 |
Why?
|
| Students | 1 | 2021 | 330 | 0.040 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 1998 | 53 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2018 | 53 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 272 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 1430 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 452 | 0.040 |
Why?
|
| Collagen | 1 | 2001 | 727 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 170 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2003 | 574 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 495 | 0.040 |
Why?
|
| Sex Factors | 2 | 2016 | 2180 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 255 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 1182 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 859 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 612 | 0.040 |
Why?
|
| Breast | 1 | 2004 | 1366 | 0.040 |
Why?
|
| Gelatinases | 1 | 1997 | 53 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 104 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 984 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2018 | 2473 | 0.040 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 84 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1027 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 900 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 98 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1998 | 124 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 272 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 4803 | 0.040 |
Why?
|
| Chest Tubes | 1 | 1998 | 118 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 122 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 721 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 438 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2008 | 2321 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 176 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2329 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2013 | 957 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 103 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2585 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 6497 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 151 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 307 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2019 | 548 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2018 | 302 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 1957 | 0.030 |
Why?
|
| Sirolimus | 2 | 2013 | 831 | 0.030 |
Why?
|
| Metagenome | 1 | 2017 | 193 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2016 | 74 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 368 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 68 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1350 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 355 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 369 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 275 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 220 | 0.030 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 37 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3662 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1998 | 228 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 396 | 0.030 |
Why?
|
| Nevada | 1 | 2015 | 6 | 0.030 |
Why?
|
| Vermont | 1 | 2015 | 6 | 0.030 |
Why?
|
| Vinblastine | 2 | 2009 | 462 | 0.030 |
Why?
|
| Oregon | 1 | 2015 | 25 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 27 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 553 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 87 | 0.030 |
Why?
|
| State Government | 1 | 2015 | 33 | 0.030 |
Why?
|
| Drainage | 1 | 1998 | 462 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2015 | 51 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 675 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 235 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2015 | 52 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 754 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2015 | 57 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2015 | 68 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 113 | 0.030 |
Why?
|
| California | 1 | 2015 | 212 | 0.030 |
Why?
|
| DNA Damage | 1 | 2003 | 1982 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 131 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2015 | 91 | 0.030 |
Why?
|
| CD146 Antigen | 2 | 2008 | 56 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 600 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 824 | 0.030 |
Why?
|
| Alleles | 3 | 2006 | 2591 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 345 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2002 | 1239 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 688 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2017 | 414 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 5160 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 195 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 296 | 0.030 |
Why?
|
| Pelvis | 2 | 2007 | 383 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 875 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2006 | 704 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 823 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 306 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 223 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 460 | 0.030 |
Why?
|
| Hematocrit | 2 | 1992 | 151 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 651 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 1442 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1069 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2008 | 964 | 0.030 |
Why?
|
| Semiconductors | 1 | 2013 | 20 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 143 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 855 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1998 | 1418 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 689 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 594 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 300 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2013 | 71 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 164 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 704 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 506 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1992 | 726 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4947 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1359 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 623 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 14 | 0.030 |
Why?
|
| Endotoxins | 1 | 1992 | 96 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 592 | 0.020 |
Why?
|
| Cathepsin B | 1 | 2011 | 35 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 3471 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2012 | 110 | 0.020 |
Why?
|
| Wound Infection | 1 | 1992 | 66 | 0.020 |
Why?
|
| Pigmentation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1571 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 507 | 0.020 |
Why?
|
| Burns | 1 | 1992 | 126 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2019 | 919 | 0.020 |
Why?
|
| Patient Care | 1 | 2012 | 151 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2015 | 882 | 0.020 |
Why?
|
| Peptide Library | 1 | 2011 | 148 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 675 | 0.020 |
Why?
|
| ADAMTS Proteins | 1 | 2010 | 15 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1992 | 191 | 0.020 |
Why?
|
| Turpentine | 1 | 1990 | 4 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 399 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1249 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 884 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 279 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2016 | 17044 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 163 | 0.020 |
Why?
|
| Corticosterone | 1 | 1990 | 123 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 875 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1990 | 97 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 1990 | 85 | 0.020 |
Why?
|
| Appetite | 1 | 1990 | 67 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 92 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3909 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 337 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 354 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 5585 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 1990 | 281 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3526 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3343 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1992 | 1586 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4476 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 124 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Sarcoma | 1 | 2020 | 1836 | 0.020 |
Why?
|
| Cisplatin | 2 | 2009 | 2497 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2013 | 1165 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 314 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 550 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2011 | 333 | 0.020 |
Why?
|
| Peptides | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Body Weight | 2 | 1992 | 1310 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 475 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 24 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 1075 | 0.020 |
Why?
|
| Groin | 1 | 2008 | 78 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 47 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 1131 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13969 | 0.020 |
Why?
|
| Suction | 1 | 2008 | 122 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2007 | 114 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1857 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1710 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 2061 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 700 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3700 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 2045 | 0.020 |
Why?
|
| Chromatin | 1 | 2013 | 1043 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 127 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 1256 | 0.020 |
Why?
|
| Laser Scanning Cytometry | 1 | 2006 | 15 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3485 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2006 | 14 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 185 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2009 | 502 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 303 | 0.020 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2006 | 57 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 470 | 0.020 |
Why?
|
| Lipids | 1 | 1990 | 653 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 64 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1109 | 0.020 |
Why?
|
| Serine | 1 | 2007 | 392 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 875 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 878 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3650 | 0.020 |
Why?
|
| Nevus, Pigmented | 1 | 2006 | 116 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 1058 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1985 | 144 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 153 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7370 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 241 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 162 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 247 | 0.020 |
Why?
|
| Birds | 1 | 1985 | 98 | 0.020 |
Why?
|
| Social Support | 1 | 2008 | 593 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 1516 | 0.020 |
Why?
|
| Purines | 1 | 2006 | 271 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1985 | 721 | 0.020 |
Why?
|
| Arginine | 1 | 2007 | 508 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 1469 | 0.010 |
Why?
|
| Emotions | 1 | 2008 | 562 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 751 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2432 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1690 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 286 | 0.010 |
Why?
|
| Interferon-beta | 1 | 2003 | 109 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 502 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 551 | 0.010 |
Why?
|
| Minority Groups | 1 | 2005 | 328 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8633 | 0.010 |
Why?
|
| Benzamides | 1 | 2008 | 1879 | 0.010 |
Why?
|
| Growth Substances | 1 | 2003 | 326 | 0.010 |
Why?
|
| Kinetics | 1 | 1985 | 2220 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2002 | 89 | 0.010 |
Why?
|
| Codon | 1 | 2002 | 261 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2001 | 60 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 713 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 564 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 2853 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 1565 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 771 | 0.010 |
Why?
|
| Brain | 1 | 2014 | 4217 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1573 | 0.010 |
Why?
|
| Edema | 1 | 2002 | 263 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1717 | 0.010 |
Why?
|
| Eating | 2 | 1992 | 446 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2006 | 1012 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5250 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5565 | 0.010 |
Why?
|
| Thoracostomy | 1 | 1998 | 47 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1997 | 136 | 0.010 |
Why?
|
| Retreatment | 1 | 1998 | 448 | 0.010 |
Why?
|
| Cyclins | 1 | 1998 | 467 | 0.010 |
Why?
|
| Arteries | 1 | 1998 | 290 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 478 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1998 | 1425 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 3999 | 0.010 |
Why?
|
| Oxygen | 1 | 1998 | 793 | 0.010 |
Why?
|
| Rats | 2 | 1992 | 6522 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 2493 | 0.010 |
Why?
|
| Acute-Phase Reaction | 1 | 1992 | 24 | 0.010 |
Why?
|
| Rats, Inbred BUF | 1 | 1992 | 26 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 473 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4357 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1992 | 213 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 1946 | 0.010 |
Why?
|
| Weight Gain | 1 | 1992 | 470 | 0.010 |
Why?
|
| Liver | 1 | 1992 | 3082 | 0.000 |
Why?
|